指南与共识中毒与环境急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

澳大利亚酒精问题治疗新指南:推荐意见概览

New Australian guidelines for the treatment of alcohol problems: an overview of recommendations.
指南 / 共识 · Med J Aust · 2021-01-01
一句话结论指南推荐在急诊常规筛查不健康饮酒(Level C),AUDIT为最有效筛查工具,酒精依赖者首选认知行为治疗联合药物治疗(Level A)。

该指南由澳大利亚发布,系统总结了酒精问题治疗的推荐意见及证据等级。筛查方面推荐在急诊和社区健康机构进行不健康饮酒筛查(Level C),AUDIT为最有效工具。治疗方面认知行为治疗为酒精依赖一线心理社会干预(Level A),阿坎酸用于维持戒断(Level A),纳曲酮用于预防重度饮酒复发(Level A),双硫仑仅在密切监督且患者有戒断动机时使用(Level A)。指南还针对孕妇、青少年、原住民、老年人等特殊人群给出推荐。

要点

  • 急诊科应实施不健康饮酒筛查和适当干预(Level C),AUDIT是最有效的筛查工具,推荐用于初级保健和医院环境。
  • 认知行为治疗应为酒精依赖的一线心理社会干预,与药物或额外心理社会干预(如动机性访谈)联合时临床获益增强(Level A)。
  • 阿坎酸推荐用于帮助维持戒酒(Level A),纳曲酮推荐用于预防重度饮酒复发(Level A)。
  • 双硫仑仅在密切监督且患者有戒断动机的设置中推荐使用(Level A)。
  • 大多数戒断病例可在门诊环境中管理(Level B),推荐地西泮递减方案(Level A)配合药房或诊所每日分阶段供药(GPP)。

适用人群与场景

  • 不健康饮酒者,筛查推荐用于全科实践(Level A)、医院(Level B)、急诊和社区健康与福利机构(Level C)。
  • 酒精依赖患者,包括需要戒断管理、药物治疗和心理社会干预者。
  • 特殊人群包括孕妇和哺乳期女性、年轻人、原住民和托雷斯海峡岛民、文化和语言多样化群体、性多样和性别多样化人群、50岁以上老年人、认知损害患者。

诊断标准与关键阈值

  • AUDIT是筛查不健康饮酒最有效的工具,推荐用于初级保健和医院环境;一般社区筛查可使用AUDIT-C作为合适替代(Level A)。
  • 数量-频率测量可检测超过当前澳大利亚指南水平的饮酒量(Level B)。
  • 间接生物学标志物应作为筛查的辅助手段(Level A),呼气和/或血液中酒精直接测量可作为近期饮酒的有用标志物(Level B)。
  • Kessler心理困扰量表(K10或K6)推荐用于筛查酒精使用障碍就诊者的共病精神障碍(Level A)。
  • 对50岁以上所有新患者应筛查有害饮酒(Level D)。

处置流程与药物剂量

  • 简短动机性访谈干预对危险水平饮酒者比不治疗更有效(Level A),在初级保健设置中最有效(Level A)。
  • 认知行为治疗应为酒精依赖的一线心理社会干预,与药物或额外心理社会干预(如动机性访谈)联合时临床获益增强(Level A)。
  • 动机性访谈在短期和较轻酒精依赖患者中有效(Level A)。
  • 阿坎酸推荐用于帮助维持戒酒(Level A);纳曲酮推荐用于预防重度饮酒复发(Level A);双硫仑仅在密切监督且患者有戒断动机的设置中推荐(Level A)。
  • 巴氯芬和托吡酯有超说明书用药证据,但副作用复杂,两者均不应作为一线药物(Level B)。
  • 大多数戒断病例可在门诊环境配合适当支持管理(Level B);推荐地西泮递减方案(Level A)配合药房或诊所每日分阶段供药(GPP)。
  • 酒精依赖孕妇应收入有成瘾专家的适当产科单位住院治疗(GPP)。
  • 老年人戒断管理可考虑较短效苯二氮䓬类药物(Level D)。

红旗征与不能漏的情况

  • 当对患者或他人安全有顾虑时,推荐专科会诊(Level C)。
  • 酒精使用障碍包括依赖可显著增加阿片类药物给药相关的过量风险;酒精和阿片类药物双重依赖者治疗前推荐专科建议(GPP)。

研究设计与关键结果

  • 该指南为澳大利亚酒精问题治疗指南,以推荐意见和证据等级形式呈现,涵盖筛查与评估、干预与治疗、 relapse预防与随访、特殊人群、共病管理等章节。
  • 筛查推荐等级:全科实践Level A、医院Level B、急诊和社区健康与福利机构Level C。
  • AUDIT为最有效筛查工具(Level A),AUDIT-C为一般社区合适替代(Level A);间接生物学标志物作为辅助(Level A)。
  • 认知行为治疗为一线心理社会干预(Level A);阿坎酸维持戒酒(Level A);纳曲酮预防重度饮酒复发(Level A);双硫仑仅限密切监督设置(Level A)。
  • 同伴支持项目如匿名戒酒会和SMART Recovery对维持戒断或减少饮酒有效(Level A)。

证据类型、等级与局限

  • 证据类型:指南(Med J Aust),采用推荐意见和证据等级体系(Level A至Level D及GPP)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 急诊科应实施不健康饮酒筛查和适当干预(Level C),AUDIT为最有效筛查工具,推荐用于医院环境。
  • 酒精依赖患者治疗应首选认知行为治疗,联合药物或额外心理社会干预可增强获益(Level A)。
  • 阿坎酸用于维持戒酒、纳曲酮用于预防重度饮酒复发(Level A);双硫仑仅用于密切监督且有戒断动机者(Level A)。
  • 大多数戒断病例可在门诊管理(Level B),采用地西泮递减方案配合每日分阶段供药(Level A/GPP)。
  • 酒精依赖孕妇应收入有成瘾专家的产科单位住院治疗(GPP);老年人戒断可考虑较短效苯二氮䓬类(Level D)。

指南或共识出处

  • New Australian guidelines for the treatment of alcohol problems: an overview of recommendations(Med J Aust)

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OF RECOMMENDATIONS AND LEVELS OF EVIDENCE: Chapter 2: Screening and assessment for unhealthy alcohol use Screening Screening for unhealthy alcohol use and appropriate interventions should be implemented in general practice (Level A), hospitals (Level B), emergency departments and community health and welfare settings (Level C). Quantity-frequency measures can detect consumption that exceeds levels in the current Australian guidelines (Level B). The Alcohol Use Disorders Identification Test (AUDIT) is the most effective screening tool and is recommended for use in primary care and hospital settings. For screening in the general community, the AUDIT-C is a suitable alternative (Level A). Indirect biological markers should be used as an adjunct to screening (Level A), and direct measures of alcohol in breath and/or blood can be useful markers of recent use (Level B). Assessment Assessment should include evaluation of alcohol use and its effects, physical examination, clinical investigations and collateral history taking (Level C). Assessment for alcohol-related physical problems, mental health problems and social support should be undertaken routinely (GPP). Where there are concerns regarding the safety of the patient or others, specialist consultation is recommended (Level C). Assessment should lead to a clear, mutually acceptable treatment plan which specifies interventions to meet the patient's needs (Level D). Sustained abstinence is the optimal outcome for most patients with alcohol dependence (Level C). Chapter 3: Caring for and managing patients with alcohol problems: interventions, treatments, relapse prevention, aftercare, and long term follow-up Brief interventions Brief motivational interviewing interventions are more effective than no treatment for people who consume alcohol at risky levels (Level A). Their effectiveness compared with standard care or alternative psychosocial interventions varies by treatment setting. They are most effective in primary care settings (Level A). Psychosocial interventions Cognitive behaviour therapy should be a first-line psychosocial intervention for alcohol dependence. Its clinical benefit is enhanced when it is combined with pharmacotherapy for alcohol dependence or an additional psychosocial intervention (eg, motivational interviewing) (Level A). Motivational interviewing is effective in the short term and in patients with less severe alcohol dependence (Level A). Residential rehabilitation may be of benefit to patients who have moderate-to-severe alcohol dependence and require a structured residential treatment setting (Level D). Alcohol withdrawal management Most cases of withdrawal can be managed in an ambulatory setting with appropriate support (Level B). Tapering diazepam regimens (Level A) with daily staged supply from a pharmacy or clinic are recommended (GPP). Pharmacotherapies for alcohol dependence Acamprosate is recommended to help maintain abstinence from alcohol (Level A). Naltrexone is recommended for prevention of relapse to heavy drinking (Level A). Disulfiram is only recommended in close supervision settings where patients are motivated for abstinence (Level A). Some evidence for off-label therapies baclofen and topiramate exists, but their side effect profiles are complex and neither should be a first-line medication (Level B). Peer support programs Peer-led support programs such as Alcoholics Anonymous and SMART Recovery are effective at maintaining abstinence or reductions in drinking (Level A). Relapse prevention, aftercare and long-term follow-up Return to problematic drinking is common and aftercare should focus on addressing factors that contribute to relapse (GPP). A harm-minimisation approach should be considered for patients who are unable to reduce their drinking (GPP). Chapter 4: Providing appropriate treatment and care to people with alcohol problems: a summary for key specific populations Gender-specific issues Screen women and men for domestic abuse (Level C). Consider child protection assessments for caregivers with alcohol use disorder (GPP). Explore contraceptive options with women of reproductive age who regularly consume alcohol (Level B). Pregnant and breastfeeding women Advise pregnant and breastfeeding women that there is no safe level of alcohol consumption (Level B). Pregnant women who are alcohol dependent should be admitted to hospital for treatment in an appropriate maternity unit that has an addiction specialist (GPP). Young people Perform a comprehensive HEEADSSS assessment for young people with alcohol problems (Level B). Treatment should focus on tangible benefits of reducing drinking through psychotherapy and engagement of family and peer networks (Level B). Aboriginal and Torres Strait Islander peoples Collaborate with Aboriginal or Torres Strait Islander health workers, organisations and communities, and seek guidance on patient engagement approaches (GPP). Use validated screening tools and consider integrated mainstream and Aboriginal or Torres Strait Islander-specific approaches to care (Level B). Culturally and linguistically diverse groups Use an appropriate method, such as the "teach-back" technique, to assess the need for language and health literacy support (Level C). Engage with culture-specific agencies as this can improve treatment access and success (Level C). Sexually diverse and gender diverse populations Be mindful that sexually diverse and gender diverse populations experience lower levels of satisfaction, connection and treatment completion (Level C). Seek to incorporate LGBTQ-specific treatment and agencies (Level C). Older people All new patients aged over 50 years should be screened for harmful alcohol use (Level D). Consider alcohol as a possible cause for older patients presenting with unexplained physical or psychological symptoms (Level D). Consider shorter acting benzodiazepines for withdrawal management (Level D). Cognitive impairment Cognitive impairment may impair engagement with treatment (Level A). Perform cognitive screening for patients who have alcohol problems and refer them for neuropsychological assessment if significant impairment is suspected (Level A).

SUMMARY OF KEY RECOMMENDATIONS AND LEVELS OF EVIDENCE: Chapter 5: Understanding and managing comorbidities for people with alcohol problems: polydrug use and dependence, co-occurring mental disorders, and physical comorbidities Polydrug use and dependence Active alcohol use disorder, including dependence, significantly increases the risk of overdose associated with the administration of opioid drugs. Specialist advice is recommended before treatment of people dependent on both alcohol and opioid drugs (GPP). Older patients requiring management of alcohol withdrawal should have their use of pharmaceutical medications reviewed, given the prevalence of polypharmacy in this age group (GPP). Smoking cessation can be undertaken in patients with alcohol dependence and/or polydrug use problems; some evidence suggests varenicline may help support reduction of both tobacco and alcohol consumption (Level C). Co-occurring mental disorders More intensive interventions are needed for people with comorbid conditions, as this population tends to have more severe problems and carries a worse prognosis than those with single pathology (GPP). The Kessler Psychological Distress Scale (K10 or K6) is recommended for screening for comorbid mental disorders in people presenting for alcohol use disorders (Level A). People with alcohol use disorder and comorbid mental disorders should be offered treatment for both disorders; care should be taken to coordinate intervention (Level C). Physical comorbidities Patients should be advised that alcohol use has no beneficial health effects. There is no clear risk-free threshold for alcohol intake. The safe dose for alcohol intake is dependent on many factors such as underlying liver disease, comorbidities, age and sex (Level A). In patients with alcohol use disorder, early recognition of the risk for liver cirrhosis is critical. Patients with cirrhosis should abstain from alcohol and should be offered referral to a hepatologist for liver disease management and to an addiction physician for management of alcohol use disorder (Level A). Alcohol abstinence reduces the risk of cancer and improves outcomes after a diagnosis of cancer (Level A).

来源:Med J Aust,查看原文。版权归原作者所有。

参考来源

  1. Haber PS, Riordan BC, Winter DT, et al. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Med J Aust. 2021. PMID: 34601742. doi:10.5694/mja2.51254

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。